Key Takeaways:
Evommune Inc.'s lead drug candidate failed a mid-stage trial, erasing more than $200 million in market value and triggering an insider trading investigation.
Evommune Inc. shares tumbled 38% after its lead drug EVO756 failed a Phase 2b trial in chronic spontaneous urticaria, wiping out a would-be rival to Novartis AG and drawing scrutiny of insider stock sales executed days before the disclosure.
"None of the three EVO756 doses showed a statistically significant effect over placebo on the Urticaria Activity Score over seven days at Week 12," Evommune said in a June 29 statement, confirming the primary endpoint miss. The trial enrolled 160 adults with moderate-to-severe CSU whose symptoms persisted despite antihistamine therapy.
The outcome removes a potential challenger to Novartis's Rhapsido, a BTK inhibitor that won FDA approval for CSU in September 2025 and generated strong early U.S. launch momentum. Evommune's stock closed at $16.45 in premarket trading Monday, down from a $25.20 close Friday and below its $17 IPO price from November 2025.
Insider Sales Draw Legal Scrutiny
The clinical failure has drawn legal attention. Levi & Korsinsky LLP opened an investigation into whether Evommune insiders possessed material non-public information when they sold shares one week before the trial results became public. Chief Executive Officer Luis C. Pena sold 7,438 shares on June 22 at prices between $22.50 and $22.99, generating about $168,916 in proceeds, according to a Form 4 filing. Chief Scientific Officer Jeegar Patel exercised 1,488 options at $3.84 per share and sold them at $22.50 the same day. Both transactions occurred under Rule 10b5-1 trading plans adopted in early March, and Form 144 filings signed by the executives affirmed they had no knowledge of material adverse information not yet publicly disclosed.
Pipeline Questions Mount
The company continues to test EVO756 in a Phase 2b atopic dermatitis trial, with data expected in the third quarter, and plans to begin dosing patients in a Phase 2b migraine prevention study. William Blair analysts warned in a June 12 note that a CSU failure would "further reduce confidence in atopic dermatitis or other itch-related indications," and said expectations for the dermatitis readout would be very low. Gil Yosipovitch, a dermatology professor at the Miller School of Medicine, told analysts that the heterogeneous inflammatory pathways involved in atopic dermatitis could complicate treatment via MRGPRX2 antagonism.
The CSU failure follows a similar setback for Incyte Corp., which paused its own MRGPRX2 antagonist EP262 in the same indication last year after preclinical toxicology concerns emerged. Incyte acquired the asset through its $750 million takeover of Escient Pharmaceuticals in 2024. Clinical data from Incyte's trial showed limited placebo-adjusted difference on the same UAS7 endpoint, suggesting the mechanism may face broader challenges in CSU beyond Evommune's specific molecule.
Evommune licensed EVO756 from Eli Lilly & Co. and has enough cash to fund operations through 2028, Pena said. The company's pipeline also includes EVO301, a Phase 1 IL-18 program that analysts said largely underpins the remaining valuation. William Blair had predicted Evommune's stock could fall to $15 on a CSU failure, a level the shares are now approaching after the 38% decline.
This article is for informational purposes only and does not constitute investment advice.
